222 related articles for article (PubMed ID: 15642976)
1. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
[TBL] [Abstract][Full Text] [Related]
2. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
3. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
4. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
5. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
[TBL] [Abstract][Full Text] [Related]
6. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.
Rumyantsev AA; Chanock RM; Murphy BR; Pletnev AG
Vaccine; 2006 Jan; 24(2):133-43. PubMed ID: 16115704
[TBL] [Abstract][Full Text] [Related]
7. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
8. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Blaney JE; Johnson DH; Firestone CY; Hanson CT; Murphy BR; Whitehead SS
J Virol; 2001 Oct; 75(20):9731-40. PubMed ID: 11559806
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
[TBL] [Abstract][Full Text] [Related]
10. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
11. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.
Pletnev AG; Swayne DE; Speicher J; Rumyantsev AA; Murphy BR
Vaccine; 2006 Sep; 24(40-41):6392-404. PubMed ID: 16831498
[TBL] [Abstract][Full Text] [Related]
12. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
13. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
Hanley KA; Goddard LB; Gilmore LE; Scott TW; Speicher J; Murphy BR; Pletnev AG
Vector Borne Zoonotic Dis; 2005; 5(1):1-10. PubMed ID: 15815144
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.
Blaney JE; Speicher J; Hanson CT; Sathe NS; Whitehead SS; Murphy BR; Pletnev AG
Vaccine; 2008 Aug; 26(33):4150-9. PubMed ID: 18586359
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
16. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.
Pletnev AG; Putnak R; Speicher J; Wagar EJ; Vaughn DW
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3036-41. PubMed ID: 11880643
[TBL] [Abstract][Full Text] [Related]
17. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
[TBL] [Abstract][Full Text] [Related]
19. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.
Kinney RM; Butrapet S; Chang GJ; Tsuchiya KR; Roehrig JT; Bhamarapravati N; Gubler DJ
Virology; 1997 Apr; 230(2):300-8. PubMed ID: 9143286
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate.
Kelly EP; Puri B; Sun W; Falgout B
Vaccine; 2010 Apr; 28(17):3030-7. PubMed ID: 19874927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
